Micro-and mesoscale aspects of neurodegeneration in engineered human neural networks carrying the LRRK2 G2019S mutation

Front Cell Neurosci. 2024 Apr 5:18:1366098. doi: 10.3389/fncel.2024.1366098. eCollection 2024.

Abstract

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have been widely linked to Parkinson's disease, where the G2019S variant has been shown to contribute uniquely to both familial and sporadic forms of the disease. LRRK2-related mutations have been extensively studied, yet the wide variety of cellular and network events related to these mutations remain poorly understood. The advancement and availability of tools for neural engineering now enable modeling of selected pathological aspects of neurodegenerative disease in human neural networks in vitro. Our study revealed distinct pathology associated dynamics in engineered human cortical neural networks carrying the LRRK2 G2019S mutation compared to healthy isogenic control neural networks. The neurons carrying the LRRK2 G2019S mutation self-organized into networks with aberrant morphology and mitochondrial dynamics, affecting emerging structure-function relationships both at the micro-and mesoscale. Taken together, the findings of our study points toward an overall heightened metabolic demand in networks carrying the LRRK2 G2019S mutation, as well as a resilience to change in response to perturbation, compared to healthy isogenic controls.

Keywords: LRRK2 G2019S mutation; Parkinsons disease (PD); human neural networks; mitochondrial dynamics; neurodegenerative disease model; structure–function.

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work and open access publication were funded by the Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology; The Liaison Committee for Education, Research and Innovation in Central Norway (Samarbeidsorganet HMN, NTNU); The Joint Research Committee between St Olav’s Hospital and the Faculty of Medicine and Health Sciences, NTNU; and the Research Council of Norway, Norwegian Micro-and Nano-Fabrication Facility, NorFab, project number 245963/F50, NTNU program for Enabling Technologies (Nanotechnology). All imaging procedures requiring the use of the EVOS2 or the Zeiss 510 META live confocal scanning microscope were performed at the Cellular and Molecular Imaging Core Facility (CMIC), Norwegian University of Science and Technology (NTNU). CMIC is funded by the Faculty of Medicine at NTNU and Central Norwegian Regional Health Authority. Helse Møre and Romsdal Hospital trust provided funding for VDV during revision and final editing of the manuscript.